MX2024003535A - Proteina mutante de interleucina-2 y fusion de la misma. - Google Patents
Proteina mutante de interleucina-2 y fusion de la misma.Info
- Publication number
- MX2024003535A MX2024003535A MX2024003535A MX2024003535A MX2024003535A MX 2024003535 A MX2024003535 A MX 2024003535A MX 2024003535 A MX2024003535 A MX 2024003535A MX 2024003535 A MX2024003535 A MX 2024003535A MX 2024003535 A MX2024003535 A MX 2024003535A
- Authority
- MX
- Mexico
- Prior art keywords
- protein
- mutant protein
- dimer
- fusion
- immunoconjugate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111110032 | 2021-09-22 | ||
| PCT/CN2022/120265 WO2023045977A1 (zh) | 2021-09-22 | 2022-09-21 | 白介素2突变体以及其融合蛋白 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024003535A true MX2024003535A (es) | 2024-05-07 |
Family
ID=85720093
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024003535A MX2024003535A (es) | 2021-09-22 | 2022-09-21 | Proteina mutante de interleucina-2 y fusion de la misma. |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20240391973A1 (enExample) |
| EP (1) | EP4406965A4 (enExample) |
| JP (2) | JP7864826B2 (enExample) |
| KR (1) | KR20240082364A (enExample) |
| CN (1) | CN118119635A (enExample) |
| AU (2) | AU2022350407B2 (enExample) |
| CA (1) | CA3233075A1 (enExample) |
| CL (1) | CL2024000834A1 (enExample) |
| CO (1) | CO2024004910A2 (enExample) |
| IL (1) | IL311643A (enExample) |
| MX (1) | MX2024003535A (enExample) |
| PE (1) | PE20241994A1 (enExample) |
| TW (1) | TWI858393B (enExample) |
| WO (1) | WO2023045977A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112105634B (zh) | 2018-09-21 | 2024-03-12 | 信达生物制药(苏州)有限公司 | 新型白介素2及其用途 |
| KR20220155316A (ko) * | 2020-03-19 | 2022-11-22 | 이노벤트 바이오로직스 (쑤저우) 컴퍼니, 리미티드 | 인터루킨-2 돌연변이 및 이의 용도 |
| WO2025007037A1 (en) * | 2023-06-28 | 2025-01-02 | Dragonfly Therapeutics, Inc. | Variant il-2 proteins |
| WO2025031434A1 (zh) * | 2023-08-08 | 2025-02-13 | 北京志道生物科技有限公司 | 经修饰的细胞因子与cd40激动剂的联用组合物及其抗肿瘤用途 |
| AU2024411090A1 (en) | 2023-12-28 | 2026-07-16 | Fortvita Biologics (Singapore) Pte. Ltd. | Pd-1/il-2r bispecific antibody fusion protein, and use and usage method thereof |
| WO2025151752A1 (en) | 2024-01-10 | 2025-07-17 | Xilio Development, Inc. | Masked il-2 cytokines and methods of use thereof |
| CN118373896B (zh) * | 2024-04-19 | 2025-07-29 | 上海科棋药业科技有限公司 | 抗pd-1抗体与il-2突变体的双功能融合蛋白 |
| WO2025252212A1 (zh) * | 2024-06-07 | 2025-12-11 | 福佑泰生物制药公司 | 抗pd-1抗体与细胞因子il-12突变蛋白的免疫缀合物以及其应用 |
| WO2026012466A1 (en) * | 2024-07-12 | 2026-01-15 | Vibrant Pharma Limited | Interleukin-2 muteins and uses thereof |
| CN118546233B (zh) * | 2024-07-30 | 2024-10-18 | 成都微芯新域生物技术有限公司 | 白介素-21突变体及其应用 |
| WO2026083295A1 (en) * | 2024-10-16 | 2026-04-23 | Bright Peak Therapeutics Ag | Trispecific compositions comprising il-2, vegf binding domains, and pd-1 binding domains |
| CN121293311B (zh) * | 2025-08-01 | 2026-07-24 | 合肥天港免疫药物有限公司 | Il-2变体及其应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4518584A (en) | 1983-04-15 | 1985-05-21 | Cetus Corporation | Human recombinant interleukin-2 muteins |
| NZ234674A (en) * | 1989-08-02 | 1992-02-25 | Seragen Inc | Mutant interleukin-2,dna encoding it, host cells, cytotoxic and toxin-mutant il-2 conjugates |
| DZ2788A1 (fr) | 1998-05-15 | 2003-12-01 | Bayer Ag | Agonistes et antagonistes selectifs à IL-2. |
| US6955807B1 (en) * | 1998-05-15 | 2005-10-18 | Bayer Pharmaceuticals Corporation | IL-2 selective agonists and antagonists |
| WO2017024465A1 (en) * | 2015-08-10 | 2017-02-16 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| JP7148539B2 (ja) * | 2017-04-03 | 2022-10-05 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 免疫抱合体 |
| KR102461885B1 (ko) | 2017-04-03 | 2022-11-03 | 에프. 호프만-라 로슈 아게 | 항-pd-1 항체와 돌연변이 il-2 또는 il-15의 면역접합체 |
| JP7765181B2 (ja) * | 2017-12-19 | 2025-11-06 | ゼンコア インコーポレイテッド | 改変されたｉｌ－２ ｆｃ融合タンパク質 |
| CN111868079B (zh) * | 2017-12-27 | 2025-06-17 | 协和麒麟株式会社 | Il-2变体 |
| CN112105634B (zh) * | 2018-09-21 | 2024-03-12 | 信达生物制药(苏州)有限公司 | 新型白介素2及其用途 |
| CA3143034A1 (en) * | 2019-06-14 | 2020-12-17 | Cugene Inc. | Novel interleukin-2 variants for the treatment of cancer |
| WO2020252421A2 (en) * | 2019-06-14 | 2020-12-17 | Cugene, Inc. | Novel interleukin-2 variants and bifunctional fusion molecules thereof |
| KR20220155316A (ko) * | 2020-03-19 | 2022-11-22 | 이노벤트 바이오로직스 (쑤저우) 컴퍼니, 리미티드 | 인터루킨-2 돌연변이 및 이의 용도 |
| WO2021185362A1 (zh) * | 2020-03-19 | 2021-09-23 | 信达生物制药(苏州)有限公司 | 白介素2突变体及其用途 |
-
2022
- 2022-09-21 JP JP2024518144A patent/JP7864826B2/ja active Active
- 2022-09-21 WO PCT/CN2022/120265 patent/WO2023045977A1/zh not_active Ceased
- 2022-09-21 PE PE2024000528A patent/PE20241994A1/es unknown
- 2022-09-21 CA CA3233075A patent/CA3233075A1/en active Pending
- 2022-09-21 IL IL311643A patent/IL311643A/en unknown
- 2022-09-21 AU AU2022350407A patent/AU2022350407B2/en active Active
- 2022-09-21 US US18/693,453 patent/US20240391973A1/en active Pending
- 2022-09-21 TW TW111135759A patent/TWI858393B/zh active
- 2022-09-21 KR KR1020247013147A patent/KR20240082364A/ko active Pending
- 2022-09-21 EP EP22872023.1A patent/EP4406965A4/en active Pending
- 2022-09-21 MX MX2024003535A patent/MX2024003535A/es unknown
- 2022-09-21 CN CN202280063868.9A patent/CN118119635A/zh active Pending
-
2024
- 2024-03-21 CL CL2024000834A patent/CL2024000834A1/es unknown
- 2024-04-18 CO CONC2024/0004910A patent/CO2024004910A2/es unknown
-
2025
- 2025-10-31 US US19/376,374 patent/US20260053898A1/en active Pending
- 2025-12-04 AU AU2025275202A patent/AU2025275202A1/en active Pending
-
2026
- 2026-02-10 JP JP2026020040A patent/JP2026097838A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW202320862A (zh) | 2023-06-01 |
| US20260053898A1 (en) | 2026-02-26 |
| EP4406965A1 (en) | 2024-07-31 |
| AU2025275202A1 (en) | 2026-02-19 |
| CO2024004910A2 (es) | 2024-07-08 |
| CA3233075A1 (en) | 2023-03-30 |
| WO2023045977A1 (zh) | 2023-03-30 |
| US20240391973A1 (en) | 2024-11-28 |
| CL2024000834A1 (es) | 2024-09-06 |
| EP4406965A4 (en) | 2025-12-17 |
| TWI858393B (zh) | 2024-10-11 |
| KR20240082364A (ko) | 2024-06-10 |
| JP2024534545A (ja) | 2024-09-20 |
| AU2022350407B2 (en) | 2025-09-04 |
| JP2026097838A (ja) | 2026-06-16 |
| AU2022350407A1 (en) | 2024-05-02 |
| CN118119635A (zh) | 2024-05-31 |
| JP7864826B2 (ja) | 2026-05-25 |
| PE20241994A1 (es) | 2024-09-27 |
| IL311643A (en) | 2024-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2024000834A1 (es) | Proteína mutante de interleucina-2 y fusión de la misma | |
| CL2022000300A1 (es) | Muteínas de interleucina 21 y sus usos para tratar tumores sólidos (divisional de la solicitud no. 202000252) | |
| CO2021012587A2 (es) | Receptores de células t mage a4 | |
| ES3064150T3 (en) | Anti-myostatin antibodies and methods of use | |
| AR126987A2 (es) | Inmunoconjugados | |
| CL2021002997A1 (es) | Construcción de reconocimiento de antígeno y su uso para el tratamiento de enfermedades proliferativas y para la detección in vitro de un cáncer (divisional de la solicitud 201901535) | |
| AR119338A1 (es) | Inmunoconjugados que comprenden un polipéptido interleuquina-2 (il-2) mutante y un anticuerpo que se une a cd8 | |
| PE20200337A1 (es) | Receptores de celulas t novedosos, e inmunoterapia usando los mismos | |
| MX2024014691A (es) | Enlazadores de conjugacion mejorados | |
| AR115389A1 (es) | Anticuerpo antagonista de cd73 | |
| MX2024009690A (es) | Anticuerpos anti-cd137 y metodos de uso de los mismos. | |
| ECSP19000282A (es) | Anticuerpos anti-b7-h3 y conjugados de anticuerpo y fármaco | |
| GT201000148A (es) | Anticuerpos antimesotelina y usos de los mismos | |
| MX2022001971A (es) | Polipeptidos de interleucina 2 (il-2) modificados, conjugados y usos de los mismos. | |
| MX2023007282A (es) | Moleculas de union al antigeno especificas para la variante ror1. | |
| PE20190436A1 (es) | Moleculas de union a antigeno que comprenden un trimero de ligando de la familia de tnf y un resto de union a pd1 | |
| MX370356B (es) | Conjugacion de anticuerpo-farmaco especifica de sitio mediante glicoingenieria. | |
| MX385679B (es) | Conjugados de farmacos de anticuerpos modificados mediante glicoingenieria. | |
| CY1116413T1 (el) | Καινοφανη πληρως-ανθρωπινα μονοκλωνικα αντισωματα anti-vap-1 | |
| BR112023005674A2 (pt) | Construtos anti-cd93 e usos dos mesmos | |
| ECSP15014133A (es) | Polipéptidos que contienen fc con glicosilación alterada y función efectora reducida | |
| CL2021002168A1 (es) | Péptido asociado a tumor; ácido nucleico; vector de expresión; célula huésped recombinante; método para producir el péptido; linfocitos t activados y su método de producción; anticuerpo; tcr; uso para tratar el cáncer; kit y composición farmacéutica; método para producir vacuna; y áptaro (divisional solicitud no. 201702407). | |
| EA202192726A1 (ru) | Magea1-специфические т-клеточные рецепторы и их использование | |
| CO2022006014A2 (es) | Terapia de tumores sólidos cd70+ utilizando linfocitos t genomodificados dirigidos a cd70 referencia cruzada a solicitudes relacionadas | |
| MX2020012775A (es) | Nuevos peptidos y nuevas combinaciones de peptidos para el uso en la inmunoterapia y metodos para crear soportes para el uso contra el cancer de pancreas y otros tipos de cancer. |